Resistant strains of bacteria feared from repeated use of ophthalmic antibiotics

Article

According to data recently published, repeated use of ophthalmic antibiotics post intraocular injections will cause an increase in incidences of resistant strains of conjunctival flora.

According to data recently published in Archives of Ophthalmology, repeated use of ophthalmic antibiotics post intraocular injections will cause an increase in incidences of resistant strains of conjunctival flora.

The study performed by Drs Stephen Kim and Hassanain Toma (Vanderbilt Eye Institute, Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA) examined 48 eyes of 24 patients who were being treated for choroidal neovascularization (CNV) with unilateral intraocular injection.

Conjunctival cultures were taken bilaterally from both eyes (treated and untreated) at baseline and after each injection. All patients were randomly assigned to one of four different antibiotics and used only that antibiotic after each injection. Antibiotic susceptibility of the bacterial isolates was measured for 16 various antibiotics and pulse-field gel electrophoresis was used to analyse the bacteria DNA.

It was found that significant increases in drug resistance occurred in treated eyes, which led the team to conclude that conjunctival flora that is repeatedly exposed to antibiotics will result in resistant strains.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.